Skip to main content

Table 1 Clinical and virological parameters

From: Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries

Patient ID

Age a

Sex b

Plasma HIV RNA Load (copies/ml)

HIV-1 Subtype c

Treatment History d

AfriPOLA

DEEPGEN

DR-0091-08

2

F

120 750

D

AZT/3TC/NVP

√

√

DR-0119-08

15

F

203 550

A

D4T/3TC/EFV

√

√

DR-0130-08

46

F

19 612

A

AZT/3TC/NVP

√

√

DR-0245-08

46

M

8052

D

AZT/3TC/NVP

√

√

DR-0292-08

61

M

29 374

C

AZT/3TC/EFV

√

√

DR-0303-08

8

M

76 044

D

AZT/3TC/NVP

√

√

DR-0370-08

43

F

50 353

A

AZT/3TC/NVP

√

√

DR-0321-09

32

F

4436

D

AZT/3TC/NVP

√

√

DR-0019-11

13

F

10 018

A

AZT/3TC/NVP

√

√

DR-0024-11

18

M

5426

D

AZT/3TC/NVP

√

√

DR-0109-08

16

F

28 354

C

d4T/3TC/EFV

√

 

DR-0116-08

2

F

15 903

CRF01_AE

AZT/3TC/NVP

√

 

DR-0118-08

11

M

216 996

D

d4T/3TC/NVP

√

 

DR-0143-08

34

M

125 575

A

d4T/3TC/EFV

√

 

DR-0224-08

46

F

3151

D

AZT/3TC/EFV

√

 

DR-0308-08

3

M

138 721

D

d4T/3TC/NVP

√

 

DR-0330-08

46

F

7989

A

d4T/3TC/NVP

√

 

DR-0344-08

3

M

138 721

D

d4T/3TC/NVP

√

 

DR-0357-08

37

F

44 876

nr

AZT/3TC/EFV

√

 

DR-0385-08

Unk

F

12 836

A

AZT/3TC/NVP

√

 

DR-0005-09

60

M

5109

D

AZT/3TC/NVP

√

 

DR-0009-09

29

F

90 781

B

AZT/3TC/NVP

√

 

DR-0056-09

17

M

41 538

A

AZT/3TC/EFV

√

 

DR-0130-09

18

M

35 136

CRF01_AE

AZT/3TC/EFV

√

 

DR-0194-09

3

F

6789

D

d4T/3TC/NVP

√

 

DR-0201-09

2

F

34 162

A

AZT/3TC/NVP

√

 

DR-0295-09

10

F

10 407

A

AZT/3TC/NVP

√

 

DR-0008-10

11

M

4226

A

AZT/3TC/EFV

√

 

DR-0019-10

6

F

3108

D

AZT/3TC/EFV

√

 

DR-0073-10

14

F

4896

A

AZT/3TC/EFV

√

 

DR-0075-10

12

M

11 680

A

AZT/3TC/EFV

√

 

DR-0077-10

53

F

Unk

A

d4T/3TC/EFV

√

 

DR-0095-10

18

F

9254

D

AZT/3TC/EFV

√

 

DR-0122-10

13

F

580 870

A

AZT/3TC/EFV

√

 

DR-0141-11

19

M

2946

A

AZT/3TC/EFV

√

 

DR-0064-10

Unk

M

110 000

D

TDF/3TC/NVP

√

√

DR-0111-09

49

F

5573

CRF01_AE

TDF/FTC/LPV-RTV

√

√

DR-0372-08

44

M

60 114

nr

TDF/FTC/NVP

√

√

DR-0242-08

Unk

F

199 519

nr

TDF/FTC/EFV

√

√

DR-0142-08

17

F

513 016

A

ABC/3TC/EFV

√

√

DR-0272-09

12

Unk

34 174

D

Unk

√

 

DR-0279-08

30

M

994 576

A

TDF/FTC/EFV

√

 

DR-0023-09

57

M

154 226

D

TDF/3TC/EFV

√

 

DR-0358-08

48

Unk

Unk

D

ddI/EFV/LPV-RTV

√

 

DR-0254-08

48

F

1983

A

TDF/3TC/LPV-RTV

√

 

DR-0319-08

34

M

193 656

D

TDF/FTC/NVP

√

 

DR-0141-08

3

M

106 478

D

ABC/3TC/NVP

√

 

DR-0230-08

10

F

7256

A

ABC/3TC/EFV

√

 

DR-0124-10

7

M

165 008

D

ABC/3TC/NVP

√

 

DR-0085-11

38

M

70 218

D

TDF/FTC/NVP

√

 
  1. a Age in years-old when known. Unk, unknown
  2. b M, male; F, female
  3. c HIV-1 subtype determined using HIV-1 reverse transcriptase (Sanger) sequences as described [13]
  4. d Antiretroviral treatment history: zidovudine, AZT; didanosine, ddI; stavudine, d4T; lamivudine, 3TC; abacavir, ABC; tenofovir, TDF; emtricitabine, FTC; nevirapine, NVP; efavirenz, EFV; ritonavir, RTV; and enfuvirtide, T-20. Unk, unknown; n.d., not determined